ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 10 of 26 for:    Primary Hyperoxaluria

A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 (ILLUMINATE-A)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03681184
Recruitment Status : Recruiting
First Posted : September 21, 2018
Last Update Posted : December 5, 2018
Sponsor:
Information provided by (Responsible Party):
Alnylam Pharmaceuticals

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of Lumasiran in Children and Adults with Primary Hyperoxaluria Type 1 (PH1).

Condition or disease Intervention/treatment Phase
Primary Hyperoxaluria Type 1 (PH1) Drug: Lumasiran Drug: Sterile Normal Saline (0.9% NaCl) Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
Actual Study Start Date : September 26, 2018
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : May 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Lumasiran (ALN-GO1) Drug: Lumasiran
Multiple doses of lumasiran by subcutaneous (SC) injection

Placebo Comparator: Sterile Normal Saline (0.9% NaCl) Drug: Sterile Normal Saline (0.9% NaCl)
Calculated volume to match experimental




Primary Outcome Measures :
  1. Percent change in 24-hour urinary oxalate excretion from baseline to Month 6 [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Absolute change in 24-hour urinary oxalate corrected for body surface area (BSA) from baseline to Month 6 [ Time Frame: 6 months ]
  2. Change in 24-hour urinary oxalate:creatinine ratio (value/upper limit of normal [ULN]) from baseline to Month 6 [ Time Frame: 6 months ]
  3. Proportion of patients with 24-hour urinary oxalate level below 1.5 x ULN at Month 6 [ Time Frame: 6 months ]
  4. Proportion of patients with 24-hour urinary oxalate level below ULN at Month 6 [ Time Frame: 6 months ]
  5. Change in estimated glomerular filtration rate (eGFR) from baseline to Month 6 [ Time Frame: 6 months ]
  6. Frequency of adverse events [ Time Frame: From treatment initiation to study completion (approximately 6 years) ]
  7. Seriousness of adverse events [ Time Frame: From treatment initiation to study completion (approximately 6 years) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Willing to provide written informed consent or assent and to comply with study requirements
  • Confirmation of PH1 disease
  • Meet the 24 hour urine oxalate excretion requirements
  • If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 90 days

Exclusion Criteria:

  • Clinically significant health concerns (with the exception of PH1) or clinical evidence of extrarenal systemic oxalosis
  • Clinically significant abnormal laboratory results
  • Known active or evidence of HIV or hepatitis B or C infection
  • An estimated GFR of <= 45 mL/min/1.73m2 at screening
  • Received an investigational agent within 30 days or 5 half-lives before the first dose of study drug or are in follow-up of another clinical study
  • History of kidney or liver transplant
  • Known history of multiple drug allergies or allergic reaction to an oligonucleotide or GalNAc
  • History of intolerance to subcutaneous injection
  • Women who are pregnant, planning a pregnancy, or breast-feeding or those of child bearing potential and not willing to use contraception
  • History of alcohol abuse within the last 12 months, or unable or unwilling to limit alcohol consumption throughout the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03681184


Contacts
Contact: Alnylam Clinical Trials Information Line 1-877-ALNYLAM clinicaltrials@alnylam.com
Contact: Alnylam Clinical Trials Information Line 1-877-256-9526

Locations
United States, Alabama
Clinical Trial Site Not yet recruiting
Birmingham, Alabama, United States, 35294
United States, California
Clinical Trial Site Recruiting
San Diego, California, United States, 92120
United States, Florida
Clinical Trial Site Recruiting
Jacksonville, Florida, United States, 32216
United States, Minnesota
Clinical Trial Site Not yet recruiting
Rochester, Minnesota, United States, 55905
United States, New York
Clinical Trial Site Not yet recruiting
New York, New York, United States, 10029
United States, Texas
Clinical Trial Site Not yet recruiting
Houston, Texas, United States, 77030
France
Clinical Trial Site Not yet recruiting
Bordeaux, France
Clinical Trial Site Not yet recruiting
Lyon, France
Clinical Trial Site Not yet recruiting
Paris, France
Germany
Clinical Trial Site Not yet recruiting
Bonn, Germany
Israel
Clinical Trial Site Not yet recruiting
Haifa, Israel
Clinical Trial Site Not yet recruiting
Jerusalem, Israel
Clinical Trial Site Not yet recruiting
Nahariya, Israel
Netherlands
Clinical Trial Site Not yet recruiting
Amsterdam, Netherlands
Switzerland
Clinical Trial Site Not yet recruiting
Bern, Switzerland
United Kingdom
Clinical Trial Site Not yet recruiting
Birmingham, United Kingdom
Clinical Trial Site Not yet recruiting
London, United Kingdom, NW3 2QG
Clinical Trial Site Not yet recruiting
London, United Kingdom, WC1N 3JH
Sponsors and Collaborators
Alnylam Pharmaceuticals
Investigators
Study Director: Tracy McGregor, MD, MSCI Alnylam Pharmaceuticals

Responsible Party: Alnylam Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03681184     History of Changes
Other Study ID Numbers: ALN-GO1-003
2018-001981-40 ( EudraCT Number )
First Posted: September 21, 2018    Key Record Dates
Last Update Posted: December 5, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Alnylam Pharmaceuticals:
PH1
Primary Hyperoxaluria
RNAi therapeutic
siRNA
AGT

Additional relevant MeSH terms:
Hyperoxaluria, Primary
Hyperoxaluria
Kidney Diseases
Urologic Diseases
Carbohydrate Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases